Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma

International Journal of Gynecological Pathology

Volumn 27, Issue 4, 2008, Pages 568-574

  Pinheiro, Céline ^a   Longatto Filho, Adhemar ^a,b   Ferreira, Luísa ^a   Pereira, Sônia Maria Miranda ^b   Etlinger, Daniela ^b   Moreira, Marise A R ^c   Jubé, Luiz Fernando ^d   Queiroz, Geraldo Silva ^d   Schmitt, Fernando ^e,f   Baltazar, Fátima ^a  

^a UNIVERSITY OF MINHO   (Portugal)

^b INSTITUTO ADOLFO LUTZ   (Brazil)

^c FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^d Hospital Araujo Jorge   (Brazil)

^e UNIVERSITY OF PORTO   (Portugal)

^f University of Porto   (Portugal)

Author keywords

Cervical carcinoma; HPV; Monocarboxylate transporters

Indexed keywords

MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 2; MONOCARBOXYLATE TRANSPORTER 4; COTRANSPORTER; MONOCARBOXYLATE TRANSPORT PROTEIN 1; MONOCARBOXYLATE TRANSPORTER; MUSCLE PROTEIN; SLC16A4 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADENOSQUAMOUS CARCINOMA; ADULT; ARTICLE; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL; SQUAMOUS CELL CARCINOMA; UTERINE CERVICITIS; UTERINE CERVIX CARCINOMA; BIOSYNTHESIS; CARCINOMA; DISEASE COURSE; FEMALE; METABOLISM; RETROSPECTIVE STUDY; UTERINE CERVIX TUMOR;

CARCINOMA; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MONOCARBOXYLIC ACID TRANSPORTERS; MUSCLE PROTEINS; NEOPLASM INVASIVENESS; RETROSPECTIVE STUDIES; SYMPORTERS; UTERINE CERVICAL NEOPLASMS;

EID: 58149192169     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31817b5b40     Document Type: Article

References (27)

1. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989;49:4373-84.
2. De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol 2005;1:779-86.
3. Schwickert G, Walenta S, Sundfor K, et al. Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res 1995;55:4757-9.
4. Walenta S, Wetterling M, Lehrke M, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000;60:916-21.
5. Brizel DM, Schroeder T, Scher RL, et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;51:349-53.
6. Walenta S, Salameh A, Lyng H, et al. Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am J Pathol 1997;150:409-15.
7. Fukumura D, Xu L, Chen Y, et al. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 2001;61:6020-4.
8. Fishbein WN, Merezhinskaya N, Foellmer JW. Relative distribution of three major lactate transporters in frozen human tissues and their localization in unfixed skeletal muscle. Muscle Nerve 2002;26:101-12.
9. Broer S, Broer A, Schneider HP, et al. Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J 1999;341:529-35.
10. Philp NJ, Yoon H, Lombardi L. Mouse MCT3 gene is expressed preferentially in retinal pigment and choroid plexus epithelia. Am J Physiol Cell Physiol 2001;280:1319-26.
11. Dimmer KS, Friedrich B, Lang F, et al. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J 2000;1:219-27.
12. Izumi H, Torigoe T, Ishiguchi H, et al. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev 2003;29:541-9.
13. Ladanyi M, Antonescu CR, Drobnjak M, et al. The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147. Am J Pathol 2002;160:1215-21.
14. Froberg MK, Gerhart DZ, Enerson BE, et al. Expression of monocarboxylate transporter MCT1 in normal and neoplastic human CNS tissues. Neuroreport 2001;12:761-5.
15. Mathupala SP, Parajuli P, Sloan AE. Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study. Neurosurgery 2004;55:1410-9.
16. Koukourakis MI, Giatromanolaki A, Harris AL, et al. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res 2006;66:632-7.
17. Pinheiro C, Longatto-Filho A, Scapulatempo C, et al. Increased expression of monocarboxylate transporters 1, 2 and 4 in colorectal carcinomas. Virchows Arch 2008;452:139-146.
18. Fang J, Quinones QJ, Holman TL, et al. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol Pharmacol 2006;70:2108-15.
19. Koukourakis MI, Giatromanolaki A, Bougioukas G, et al. Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. Cancer Biol Ther 2007;6:1476-9.
20. Tavassoli FA, Deville P, eds. Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumours. Lyon: IARC Press; 2003;259-89.
21. Kirk P, Wilson MC, Heddle C, et al. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J 2000;19:3896-904.
22. Wilson MC, Meredith D, Fox JE, et al. Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: the ancillary protein for the insensitive MCT2 is EMBIGIN (gp70). J Biol Chem 2005;280:27213-21.
23. Yasuda S, Kojima A, Maeno Y, et al. Poor prognosis of patients with stage Ib1 adenosquamous cell carcinoma of the uterine cervix with pelvic lymphnode metastasis. Kobe J Med Sci 2006;52:9-15.
24. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007;7:11-22.
25. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003;31:14-9.
26. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (London) 2006;110:525-41.
27. Snoeck R. Papillomavirus and treatment. Antiviral Res 2006;71:181-91.